• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Heartbeam Inc. (Amendment)

    2/13/23 5:25:12 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care
    Get the next $BEAT alert in real time by email
    SC 13G/A 1 g083404_sc-13ga.htm SC 13G/A

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934
    (Amendment No. 2)*

     

    HeartBeam, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

     

    42238H108

    (CUSIP Number)

     

    December 31, 2022

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)
    ☒ Rule 13d-1(c)
    ☐ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    CUSIP No. 42238H108

      13G   Page 2 of 9 Pages
       
    1. NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Ionic Ventures, LLC
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ☐
    (b)    ☒
    3. SEC USE ONLY
     
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
     
    California, United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5. SOLE VOTING POWER
     
    0
    6.

    SHARED VOTING POWER

     

    41,519 (1)

    7. SOLE DISPOSITIVE POWER
     
    0
    8.

    SHARED DISPOSITIVE POWER

     

    41,519 (1)

    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    41,519 (1)
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ☐
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.52%
    12. TYPE OF REPORTING PERSON (see instructions)

    OO
    (1)As more fully described in Item 4, the number of shares beneficially owned consists of 41,519 shares of Common Stock to be issued upon the exercise of shares of Warrants held by the Reporting Persons.

     

     

     

     

    CUSIP No. 42238H108   13G   Page 3 of 9 Pages
       
    1. NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Brendan O’Neil
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ☐
    (b)    ☒
    3. SEC USE ONLY
     
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5. SOLE VOTING POWER
     
    0
    6. SHARED VOTING POWER
     
    41,519 (1)
    7. SOLE DISPOSITIVE POWER
     
    0
    8. SHARED DISPOSITIVE POWER
     
    41,519 (1)

    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    41,519 (1)
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ☐
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.52%
    12. TYPE OF REPORTING PERSON (see instructions)

    IN
    (1)As more fully described in Item 4, the number of shares beneficially owned consists of 41,519 shares of Common Stock to be issued upon the exercise of shares of Warrants held by the Reporting Persons.

     

     

     

     

    CUSIP No. 42238H108   13G   Page 4 of 9 Pages
       
    1. NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Keith Coulston
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ☐
    (b)    ☒
    3. SEC USE ONLY
     
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5. SOLE VOTING POWER
     
    0
    6. SHARED VOTING POWER
     
    41,519 (1)
    7. SOLE DISPOSITIVE POWER
     
    0
    8. SHARED DISPOSITIVE POWER
     
    41,519 (1)

    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    41,519 (1)
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ☐
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.52%
    12. TYPE OF REPORTING PERSON (see instructions)

    IN
    (1)As more fully described in Item 4, the number of shares beneficially owned consists of 41,519 shares of Common Stock to be issued upon the exercise of shares of Warrants held by the Reporting Persons.

     

     

     

     

    CUSIP No. 42238H108   13G   Page 5 of 9 Pages

     

    Item 1(a). Name of Issuer:

     

    HeartBeam, Inc. (the “Issuer”).

     

    Item 1(b). Address of Issuer’s Principal Executive Offices:

     

    The Issuer’s principal executive offices are located at 2118 Walsh Ave., Suite 210, Santa Clara, CA 95050.

     

    Item 2(a). Names of Persons Filing:

     

    This statement is filed by:
       
      (i) Ionic Ventures LLC, a California limited liability company (“Ionic”);
       
      (ii) Brendan O’Neil (“Mr. O’Neil”); and
       
      (iii)  Keith Coulston (“Mr. Coulston”).

     

    The foregoing persons are hereinafter sometimes collectively referred to as the (“Reporting Persons”). Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.

     

    The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 1, pursuant to which they have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Act.

     

    The filing of this statement should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the securities reported herein.  

     

    Item 2(b). Address of Principal Business Office or, if none, Residence:

     

    The principal business address of each of the Reporting Persons is 3053 Fillmore St, Suite 256, San Francisco, CA 94123.

     

    Item 2(c). Citizenship:

     

    Ionic is a limited liability company organized under the laws of California. Each of Mr. O’Neil and Mr. Coulston is a citizen of the United States.

     

    Item 2(d). Title of Class of Securities:

     

    The title of the class of securities to which this statement relates is Common Stock, par value $0.0001 per share.

     

    Item 2(e). CUSIP Number:

     

    42238H108

     

     

     

     

    CUSIP No. 42238H108   13G   Page 6 of 9 Pages

     

    Item 3. If This Statement is Filed Pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), Check Whether the Person Filing is a:

     

    Not applicable.

     

    Item 4. Ownership.

     

    The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G and is incorporated herein by reference for each such Reporting Person. The ownership percentages reported are based on (i) 8,009,743 shares of Common Stock outstanding as of December 31, 2022 as reported in the Issuer’s Registration Statement on Form S-3 filed with the U.S. Securities and Exchange Commission on February 2, 2023 and (ii) 41,519 shares of Common Stock that are issuable upon exercise of the warrants (the “Warrants”) that are held by the Reporting Persons.

     

    As of December 31, 2022, the Reporting Persons hold 41,519 shares of Common Stock issuable upon full exercise of the Warrants held by the Reporting Persons.

     

    As of December 31, 2022, Ionic is the beneficial owner of 41,519 shares of Common Stock (the “Shares”). Ionic has the power to dispose of and the power to vote the Shares beneficially owned by it, which power may be exercised by its managers, Mr. O’Neil and Mr. Coulston. Mr. O’Neil and Mr. Coulston, as managers of Ionic, have shared power to vote and/or dispose of the Shares beneficially owned by Ionic. Neither Mr. O’Neil nor Mr. Coulston directly owns any Common Stock of the Issuer. By reason of the provisions of Rule 13d-3 of the Act, each of Mr. O’Neil and Mr. Coulston may be deemed to beneficially own the Shares beneficially owned by Ionic.

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

     

     

     

    CUSIP No. 42238H108   13G   Page 7 of 9 Pages

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10. Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

    CUSIP No. 42238H108   13G   Page 8 of 9 Pages

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 13, 2023 IONIC VENTURES, LLC
       
      /s/ Keith Coulston
      Name: Keith Coulston
      Title: Partner
       
      /s/ Brendan O’Neil
      Brendan O’Neil
       
      /s/ Keith Coulston
      Keith Coulston

     

     

     

     

    CUSIP No. 42238H108   13G   Page 9 of 9 Pages

     

    EXHIBIT 1

     

    JOINT FILING AGREEMENT

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. The undersigned hereby further agree that this Joint Filing Agreement may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original, but all of which counterparts shall together constitute one and the same instrument.

     

    Date: February 13, 2023 IONIC VENTURES, LLC
       
      /s/ Keith Coulston
      Name: Keith Coulston
      Title: Partner
       
      /s/ Brendan O’Neil
      Brendan O’Neil
       
      /s/ Keith Coulston
      Keith Coulston

     

     

    Get the next $BEAT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BEAT

    DatePrice TargetRatingAnalyst
    12/20/2021$9.00Speculative Buy
    Benchmark
    More analyst ratings

    $BEAT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Benchmark initiated coverage on BioTelemetry with a new price target

    Benchmark initiated coverage of BioTelemetry with a rating of Speculative Buy and set a new price target of $9.00

    12/20/21 7:19:06 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    $BEAT
    SEC Filings

    View All

    SEC Form 10-Q filed by Heartbeam Inc.

    10-Q - HeartBeam, Inc. (0001779372) (Filer)

    8/13/25 4:02:27 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    Heartbeam Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - HeartBeam, Inc. (0001779372) (Filer)

    7/16/25 2:15:18 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    SEC Form DEF 14A filed by Heartbeam Inc.

    DEF 14A - HeartBeam, Inc. (0001779372) (Filer)

    5/28/25 9:12:56 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    $BEAT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    HeartBeam Reports Second Quarter 2025 Results

    Executing on Commercial Readiness Plans in Anticipation of FDA 510(k) Clearance for Groundbreaking 12-lead Electrocardiogram (ECG) Synthesis Software Engaged in Ongoing Productive Discussions with FDA Related to the 510(k) Application Increased Business Development Resources to Match Inbound Interest from Industry Partners Management to Host Webcast and Conference Call Today at 4:30 p.m. ET HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, has reported its financial and operational results for the second quarter ended June 30, 2025. Second Quarter & Subsequent 2025 Operational Highligh

    8/13/25 4:01:00 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    HeartBeam to Host Second Quarter 2025 Results Conference Call on Wednesday, August 13, 2025 at 4:30 p.m. Eastern Time

    HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, will hold a conference call on Wednesday, August 13, 2025 at 4:30 p.m. Eastern time to discuss its results for the second quarter ended June 30, 2025, and will be providing updates on regulatory initiatives, commercial-readiness activities and anticipated milestones. A press release detailing these results will be issued prior to the call. HeartBeam CEO Robert Eno and CFO Timothy Cruickshank will host the conference call, followed by a question-and-answer period. The conference call will be accompanied by a presentation, which can be viewed during t

    7/30/25 7:00:00 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    HeartBeam Wins Industry Innovation Award for Advancing Remote Cardiac Care With Groundbreaking ECG Technology

    FDA-cleared technology makes clinical-grade ECG insights for arrhythmia assessment available outside of a medical facility HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced it has been awarded the Innovation Award in Remote Cardiac Diagnostics as part of the 2025 Medical Device Network Excellence Awards. The award honors HeartBeam's groundbreaking, FDA-cleared electrocardiogram (ECG) technology that enables clinical-grade diagnostics for arrhythmia assessment outside of traditional healthcare settings, expanding access to timely and actionable cardiac care. The Medical Device Netw

    7/22/25 7:00:00 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    $BEAT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Cruickshank Tim

    4 - HeartBeam, Inc. (0001779372) (Issuer)

    5/1/25 11:06:06 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Executive Officer Eno Robert Paul

    4 - HeartBeam, Inc. (0001779372) (Issuer)

    5/1/25 11:05:46 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Technology Officer Persen Kenneth Harry

    4 - HeartBeam, Inc. (0001779372) (Issuer)

    5/1/25 11:03:46 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    $BEAT
    Financials

    Live finance-specific insights

    View All

    HeartBeam Reports Second Quarter 2025 Results

    Executing on Commercial Readiness Plans in Anticipation of FDA 510(k) Clearance for Groundbreaking 12-lead Electrocardiogram (ECG) Synthesis Software Engaged in Ongoing Productive Discussions with FDA Related to the 510(k) Application Increased Business Development Resources to Match Inbound Interest from Industry Partners Management to Host Webcast and Conference Call Today at 4:30 p.m. ET HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, has reported its financial and operational results for the second quarter ended June 30, 2025. Second Quarter & Subsequent 2025 Operational Highligh

    8/13/25 4:01:00 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    HeartBeam to Host Second Quarter 2025 Results Conference Call on Wednesday, August 13, 2025 at 4:30 p.m. Eastern Time

    HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, will hold a conference call on Wednesday, August 13, 2025 at 4:30 p.m. Eastern time to discuss its results for the second quarter ended June 30, 2025, and will be providing updates on regulatory initiatives, commercial-readiness activities and anticipated milestones. A press release detailing these results will be issued prior to the call. HeartBeam CEO Robert Eno and CFO Timothy Cruickshank will host the conference call, followed by a question-and-answer period. The conference call will be accompanied by a presentation, which can be viewed during t

    7/30/25 7:00:00 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    HeartBeam to Host First Quarter 2025 Results Conference Call on Tuesday, May 13, 2025 at 4:30 p.m. Eastern Time

    HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, will hold a conference call on Tuesday, May 13, 2025 at 4:30 p.m. Eastern time to discuss its results for the first quarter ended March 31, 2025, and will be providing updates on regulatory initiatives, commercial-readiness activities and anticipated milestones. A press release detailing these results will be issued prior to the call. HeartBeam CEO Robert Eno and CFO Timothy Cruickshank will host the conference call, followed by a question-and-answer period. The conference call will be accompanied by a presentation, which can be viewed during the web

    5/1/25 8:31:00 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    $BEAT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Heartbeam Inc.

    SC 13D - HeartBeam, Inc. (0001779372) (Subject)

    10/25/23 4:01:55 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D filed by Heartbeam Inc.

    SC 13D - HeartBeam, Inc. (0001779372) (Subject)

    8/28/23 4:26:34 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D filed by Heartbeam Inc.

    SC 13D - HeartBeam, Inc. (0001779372) (Subject)

    6/2/23 2:36:13 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    $BEAT
    Leadership Updates

    Live Leadership Updates

    View All

    HeartBeam Appoints CEO Robert Eno to Board of Directors to Support U.S. Commercialization and Growth

    Board expansion reflects Company's commitment to leadership and innovation in remote cardiac monitoring HeartBeam, Inc., (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced the appointment of Chief Executive Officer, Robert Eno, to its Board of Directors. As the Company continues to make significant advancements towards commercial readiness, the Board elected to expand from eight to nine members to accommodate this addition. Mr. Eno joined HeartBeam as President in January 2023 and was appointed CEO in October 2024. With over 30 years of experience in the medical technology industry, he has a proven

    5/5/25 7:00:00 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    HeartBeam Announces FDA Clearance for At-Home, High-Fidelity Heart Monitoring Technology

    First cable-free, ambulatory ECG that captures the heart's electrical signals from three distinct directions for high-fidelity data collection and advanced diagnostics Patients can have the credit card-sized device with them at all times, ready to record an ECG whenever they feel symptoms and reduce delays in care Company to initiate Early Access Program to gain important patient and physician feedback on the use of the system in preparation for commercial launch HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that the US Food and Drug Administration (FDA) has granted 510(k) cl

    12/16/24 8:31:00 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    HeartBeam Appoints Robert Eno as Chief Executive Officer in Preparation for US Commercialization

    Industry leader brings extensive experience in developing go-to-market strategies for breakthrough products and delivering growth Founder and current CEO Branislav Vajdic named President to focus on advancing the Company's groundbreaking vector-based technology for heart health, including AI applications HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful insights wherever the patient is, announced that Robert Eno has been appointed Chief Executive Officer (CEO), effective Monday, October 21, 2024. The seasoned MedTech executive joined HeartBeam as President in January 2023 and will lead as the Company continues to work

    10/17/24 8:31:00 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    $BEAT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ferrari Richard bought $50,000 worth of shares (29,412 units at $1.70), increasing direct ownership by 20% to 179,136 units (SEC Form 4)

    4 - HeartBeam, Inc. (0001779372) (Issuer)

    2/21/25 8:00:22 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    CFO Cruickshank Tim bought $30,000 worth of shares (17,647 units at $1.70) (SEC Form 4)

    4 - HeartBeam, Inc. (0001779372) (Issuer)

    2/21/25 7:55:14 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care